Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,799 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07106723RecruitingPhase 2
Study of stem cell transplant and CD7-CART for T-cell lymphoma
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07106814RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy (Meta10-TIL) made from your own immune cells that were trained to attack cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including cervical, liver, lung, breast, ovarian, head and neck, or colorectal cancer.
Hefei, AnhuiAges 19–70 - NCT07106892RecruitingPhase 2
Testing HLX43 for advanced colorectal cancer
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
BeijingAges 3 weeks–2 months - NCT07107659RecruitingEarly Phase 1
Testing ONT01 for active lupus
This trial tests a new drug called ONT01 for people with active lupus that is not affecting their kidneys. It is for those who have not had success with standard treatments.
New York, New YorkAges 18 years+ - NCT07108127RecruitingPhase 2
Targeted drugs plus chemo for HER2-positive rectal cancer
This trial tests whether a combination of two targeted drugs (trastuzumab and pertuzumab biosimilars) plus chemotherapy can shrink advanced HER2-positive rectal cancer before surgery. It aims to improve response and potentially reduce the need for more aggressive treatments.
BeijingAges 18 years+ - NCT07110415RecruitingPhase 4
Yangxinshi tablets for heart disease with reduced heart function
This trial tests whether Yangxinshi tablets can help people with coronary heart disease and some degree of heart failure. It looks at improving heart function and safety over the treatment period.
Haozhou, AnhuiAges 40–80 - NCT07113262RecruitingPhase 3
Study of IBI311 for people with inactive thyroid eye disease
This trial tests a new medication called IBI311 for people whose thyroid eye disease is no longer active but still causes bulging eyes. It aims to see if the drug can reduce eye bulging safely.
Shenyang, LiaoningAges 18–80 - NCT07114159Recruiting
Sacral nerve stimulation for ulcerative colitis
This trial tests if sacral nerve stimulation can safely help people with ulcerative colitis that hasn't improved with standard treatments. It aims to see if this approach can reduce symptoms and improve quality of life.
Xi'an, ShaanxiAges 18–65 - NCT07114419RecruitingPhase 2
New weekly injection for weight loss in overweight or obesity
This study tests a new weekly injection, efsubaglutide alfa (a GLP-1 drug), for helping people with overweight or obesity lose weight. It is for people who have not been able to lose weight with diet and exercise alone and do not have other serious health conditions.
BrookvaleAges 18–75 - NCT07115082RecruitingPhase 1/Phase 2
Stem cells from amniotic fluid for early menopause
This study tests whether stem cells from the fluid around a baby (amniotic membrane) can help women with premature ovarian insufficiency improve their chances of getting pregnant. It is designed for women under 40 who have not had a period for months and have high FSH levels.
ShanghaiAges 20–40 - NCT07115277Recruiting
A new imaging test for prostate cancer that has come back
This study tests a new imaging drug called Flotufolastat F-18 to find prostate cancer that has returned after treatment. The goal is to see how well and safely it finds the cancer spots, which could help guide next steps.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07115992Recruiting
Surgery with or without radiation for prostate cancer
This trial compares radical prostatectomy (surgery to remove the prostate) alone versus surgery plus pelvic lymph node removal, with or without additional radiation, for men with intermediate- or high-risk prostate cancer that has not spread. It aims to see which approach is more effective and safe.
ShanghaiAges 18–80 - NCT07117864Recruiting
T-DXd with brain radiation for HER2+ breast cancer
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07119021RecruitingPhase 4
Ultra-early stroke treatment with neuroprotection and clot removal
This trial tests a new approach for treating acute ischemic stroke within 4.5 hours of symptoms starting. It combines a special mobile stroke unit that delivers early brain-protecting medicine with standard clot-busting or clot-removal procedures, to see if this can improve recovery.
BeijingAges 18–80 - NCT07119372RecruitingPhase 3
New drug for anemia from kidney disease on dialysis
This trial tests a new drug called BCD-131 (a biosimilar to Mircera) for treating anemia in people with kidney disease on dialysis. It compares the new drug to the standard treatment to see if it works just as well and is safe.
MinskAges 18–75 - NCT07120282RecruitingPhase 2
Tislelizumab after surgery for early-stage lung cancer
This trial tests whether a drug called tislelizumab, given after surgery, can help prevent lung cancer from coming back. It is for people with stage I non-small cell lung cancer who have certain high-risk features and a protein called PD-L1 on their tumor cells.
BeijingAges 18 years+ - NCT07122167Recruiting
Study of a drug-coated stent for blocked leg arteries
This study is testing a new drug-coated stent for blocked arteries in the thigh or behind the knee. It may help people with moderate to severe leg pain or wounds by improving blood flow without needing surgery.
Chrzanów, ChrzanowAges 18–80 - NCT07126782RecruitingEarly Phase 1
Gene-edited immune cells for AML after transplant
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
BeijingAges 18 years+ - NCT07128979RecruitingPhase 4
Studying butcher’s broom for moderate hemorrhoids
This study tests a plant-based medication made from butcher’s broom (Ruscus aculeatus) to see if it safely helps people with moderate hemorrhoids. If you have stage II or III hemorrhoids and are between 18 and 45, you may be able to join.
IstanbulAges 18–45 - NCT07130032RecruitingPhase 2
Immunotherapy combo for advanced lung cancer or melanoma
This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT07131254RecruitingEarly Phase 1
Study of GT719 cell therapy for CD19-positive leukemia or lymphoma
This study is testing a new cell therapy called GT719 for people with B-cell leukemia or lymphoma that has not responded to standard treatments. The therapy targets a protein called CD19 on cancer cells, aiming to kill them.
Ganzhou, JiangxiAges 18–75 - NCT07131813RecruitingPhase 4
Tofacitinib for oral lichen planus
This trial tests whether adding the drug tofacitinib to standard treatment helps reduce symptoms of oral lichen planus, a chronic inflammatory mouth condition. It is for people with moderate to severe disease who have not taken certain immune-suppressing medicines recently.
Bhubaneswar, OdishaAges 18 years+ - NCT07132567Recruiting
Studying safety and effectiveness of Poteligeo for certain skin lymphomas
This study is tracking the safety and effectiveness of a drug called Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome who have already tried at least one body-wide treatment. It is a post-market surveillance study, meaning the drug is already approved, and doctors are gathering real-world information about how well it works and any side effects.
Busan, Busan Metropolitan CityAges 19 years+ - NCT07132775Recruiting
Full-body electrical stimulation suit for spasticity and pain
This study tests a full-body suit that uses mild electrical stimulation to help reduce spasticity, pain, and overactive reflexes in people with conditions like Multiple Sclerosis or Fibromyalgia. It aims to see if the suit is safe and can improve comfort and movement.
Chicago, IllinoisAges 18–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,799 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.